Ocera Therapeutics (OCRX) Commences Phase 2A Study with Oral OCR-002 in Patients with Cirrhosis
Tweet Send to a Friend
Ocera Therapeutics, Inc. (NASDAQ: OCRX), today announced the dosing of the first patients in Part Two of a Phase1/Phase 2a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
